September 22, 2016
(Scientific American) – The FDA notes the revised guidelines are meant to help manufacturers navigate regulations that are already in place. But many interpret them as a crackdown on clinics offering patients experimental procedures. “It is possible that after these public meetings the FDA may step up its activities on clinics to a more proportionate level and send a signal that it is indeed going to rein in the dangerous stem cell clinic industry for real,” says Paul Knoepfler, a professor of cell biology at the University of California, Davis, who specializes in stem cells.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.